Lipocine Inc (LPCN)

NASDAQ
Currency in USD
3.2600
-0.0200(-0.61%)
Closed·
After Hours
3.4300+0.1700(+5.2147%)
·
LPCN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual Post-Market activity
Fair Value
Day's Range
3.26003.4460
52 wk Range
2.750011.7900
Key Statistics
Edit
Prev. Close
3.28
Open
3.32
Day's Range
3.26-3.446
52 wk Range
2.75-11.79
Volume
7.43K
Average Volume (3m)
16.08K
1-Year Change
-31.08%
Book Value / Share
3.93
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LPCN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
6.7500
Upside
+107.06%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

Lipocine Inc Company Profile

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company’s pipeline candidates also include LPCN 1111 (TLANDO XR), a next-generation long-acting oral product candidate for TRT; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the treatment of cirrhosis; LPCN 1154 to treat postpartum depression; LPCN 2101, a NAS candidate for women with epilepsy; and LPCN 2203, an oral candidate for management of essential tremor. It also develops LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of metabolic dysfunction-associated steatohepatitis; LPCN 2401 to improve body composition in obesity management; and LPCN 1107, an oral hydroxy progesterone caproate product indicated for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Compare LPCN to Peers and Sector

Metrics to compare
LPCN
Peers
Sector
Relationship
P/E Ratio
2,088.4x−0.4x−0.5x
PEG Ratio
21.020.010.00
Price/Book
0.8x1.5x2.6x
Price / LTM Sales
1.6x2.6x2.9x
Upside (Analyst Target)
105.8%116.1%56.4%
Fair Value Upside
Unlock21.6%9.3%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 6.7500
(+107.06% Upside)

Earnings

Latest Release
Aug 09, 2023
EPS / Forecast
-- / -0.425
Revenue / Forecast
-- / 934.00K
EPS Revisions
Last 90 days

People Also Watch

9.65
PONY
-6.49%
0.5660
APVO
-7.52%
0.4320
RNAZ
+2.42%
1.130
WINT
-0.88%
0.944
SCNX
-6.53%

FAQ

What Is the Lipocine (LPCN) Stock Price Today?

The Lipocine stock price today is 3.26

What Stock Exchange Does Lipocine Trade On?

Lipocine is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Lipocine?

The stock symbol for Lipocine is "LPCN."

What Is the Lipocine Market Cap?

As of today, Lipocine market cap is 17.76M.

What is Lipocine Earnings Per Share?

The Lipocine EPS is 0.00.

From a Technical Analysis Perspective, Is LPCN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.